Short Interest in The Oncology Institute, Inc. (NASDAQ:TOI) Increases By 39.6%
Short Interest in The Oncology Institute, Inc. (NASDAQ:TOI) Increases By 39.6%
The Oncology Institute, Inc. (NASDAQ:TOI – Get Rating) was the target of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 1,090,000 shares, a growth of 39.6% from the November 30th total of 780,600 shares. Approximately 4.2% of the shares of the company are sold short. Based on an average trading volume of 193,100 shares, the short-interest ratio is currently 5.6 days.
肿瘤研究所,Inc.(纳斯达克:TOI-GET评级)是空头股数12月份显著增长的目标。截至12月15日,空头股数共有109万股,比11月30日的78.06万股增长39.6%。该公司约4.2%的股份被卖空。以平均成交量19.31万股计算,目前短息比为5.6天。
Oncology Institute Stock Performance
肿瘤研究所股票表现
TOI stock traded up $0.06 during mid-day trading on Friday, reaching $1.65. 187,771 shares of the stock traded hands, compared to its average volume of 140,027. The business has a 50-day moving average price of $2.25 and a two-hundred day moving average price of $4.51. The company has a current ratio of 4.37, a quick ratio of 4.07 and a debt-to-equity ratio of 0.62. Oncology Institute has a one year low of $0.86 and a one year high of $10.74.
TOI股价在周五午盘交易中上涨0.06美元,达到1.65美元。该股共有187,771股易手,而其平均成交量为140,027股。该业务的50日移动均线价格为2.25美元,200日移动均线价格为4.51美元。该公司的流动比率为4.37,速动比率为4.07,债务权益比率为0.62。肿瘤学研究所的一年低点为0.86美元,一年高位为10.74美元。
Insiders Place Their Bets
内部人士下注
In related news, COO Matthew P. Miller bought 73,684 shares of the firm's stock in a transaction that occurred on Friday, December 16th. The shares were bought at an average cost of $0.95 per share, with a total value of $69,999.80. Following the acquisition, the chief operating officer now owns 175,325 shares in the company, valued at $166,558.75. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, COO Matthew P. Miller bought 73,684 shares of Oncology Institute stock in a transaction that occurred on Friday, December 16th. The stock was bought at an average cost of $0.95 per share, with a total value of $69,999.80. Following the acquisition, the chief operating officer now owns 175,325 shares of the company's stock, valued at approximately $166,558.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mohit Kaushal sold 15,994 shares of the firm's stock in a transaction that occurred on Monday, November 14th. The stock was sold at an average price of $2.13, for a total transaction of $34,067.22. Following the sale, the director now owns 25,534 shares in the company, valued at approximately $54,387.42. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 881,195 shares of company stock worth $3,000,612. Company insiders own 10.40% of the company's stock.
在相关新闻中,首席运营官马修·P·米勒在12月16日星期五的一次交易中购买了73,684股该公司的股票。这些股票是以每股0.95美元的平均成本购买的,总价值为69,999.80美元。收购完成后,这位首席运营官现在拥有该公司175,325股股票,价值166,558.75美元。此次收购是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过这个环节。在其他新闻方面,首席运营官马修·P·米勒在12月16日星期五的一笔交易中购买了73,684股肿瘤研究所的股票。这只股票是以每股0.95美元的平均价格购买的,总价值为69,999.80美元。收购完成后,首席运营官现在拥有该公司175,325股股票,价值约为166,558.75美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可以通过这个环节。此外,在11月14日星期一的一笔交易中,董事莫希特·考沙尔出售了15,994股该公司股票。该股以2.13美元的平均价格出售,总成交金额为34,067.22美元。交易完成后,董事现在拥有该公司25,534股股份,价值约54,387.42美元。关于这次销售的披露可以找到这里。在过去的90天里,内部人士卖出了881,195股公司股票,价值3,000,612美元。公司内部人士持有该公司10.40%的股份。
Institutional Investors Weigh In On Oncology Institute
机构投资者看好肿瘤学研究所
Analyst Ratings Changes
分析师评级发生变化
Separately, Guggenheim cut their target price on shares of Oncology Institute from $7.00 to $6.00 and set a "buy" rating for the company in a research note on Friday, November 11th.
另外,Guggenheim在11月11日星期五的一份研究报告中将肿瘤学研究所的股票目标价从7.00美元下调至6.00美元,并为该公司设定了“买入”评级。
Oncology Institute Company Profile
肿瘤学研究所公司简介
(Get Rating)
(获取评级)
The Oncology Institute, Inc, an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services.
肿瘤学研究所是一家肿瘤学公司,在美国提供内科肿瘤学服务。它的服务包括医生服务、内部输液和药房、临床试验服务、放射治疗、门诊干细胞移植和输血计划以及患者支持。该公司还提供和管理临床试验服务,如管理临床试验、姑息治疗计划和干细胞移植服务。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Oncology Institute (TOI)
- The Dogs Of Tech: It's Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Is Kintara Therapeutics A Hidden Gem?
- Should You Warm up to Generac Stock for the Winter?
- 3 High-Yield Dividend Stocks to Hold for the Long Haul
- 免费获取StockNews.com关于肿瘤研究所(TOI)的研究报告
- 科技狗:是时候咬一口这些股票了
- 这笔收购会让微软成为熊市买入者吗?
- 金塔拉治疗公司是一颗隐藏的宝石吗?
- 你应该热身到Generac股票过冬吗?
- 长期持有的3只高收益股利股票
Receive News & Ratings for Oncology Institute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncology Institute and related companies with MarketBeat.com's FREE daily email newsletter.
接受肿瘤学研究所每日新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收肿瘤学研究所和相关公司的最新新闻和分析师评级的每日简明摘要。